patients in need.” Dr. Tatsis has extensive senior-level leadership experience in global biopharmaceuticals companies. In 2017, Dr. Tatsis joined Vertex Pharmaceuticals and is responsible for managing all aspects of global regulatory affairs and...
announced the appointment of Zivjena Vucetic, M.D., Ph.D., as Chief Medical Officer. A physician-scientist with more than 15 years of experience in diagnostics and emerging platforms, Dr. Vucetic has directed medical and scientific strategies that...
that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CTx001, the company's lead gene therapy candidate. The IND clearance enables initiation of the Opti-GAIN Phase I/II clinical trial in...
serve various industries, including pharma, biotech, chemicals, food and beverage, oil and gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For...
with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). After 18 months of LEQEMBI (lecanemab-irmb) intravenous (IV) treatment at 10 mg/kg every two weeks, patients may either continue IV...
our position as the global leader of transplant solutions.” Product Launches and Technology Previews at ASHI 2025 AlloSeq Tx11: Launching at ASHI 2025, this next-generation HLA typing solution features enhanced Class II coverage to improve...
†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024). About iCRYO Founded in 2015, iCRYO’s mission is to elevate the quality of life of its team members, guests,...
approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. Rhapsido is a pill taken twice daily and does not require injections or lab monitoring. It is the...
These products address indications within the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with...
not all of the possible side effects of ENBUMYST. To report suspected adverse reactions, contact Corstasis Therapeutics at 1-877-300-5339 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. About Corstasis Therapeutics: Corstasis Therapeutics Inc. is...
mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) in China. After 18 months of a dosing regimen of 10 mg/kg once every two weeks during initiation phase, a transition to the maintenance dosing...
ejection fraction (LVEF) ≥40%, following the agency’s Priority Review of its supplemental New Drug Application (sNDA).1 Since July 2021, KERENDIA has been approved to reduce the risk of CV death, hospitalization for HF, non-fatal myocardial...
Emulsion 0.05%. According to IQVIA, the Difluprednate Ophthalmic Emulsion market had U.S. sales of approximately $18 million*. The Therapeutic Equivalence (TE) code for Upsher-Smith's Difluprednate Ophthalmic Emulsion product is AB, and the...
macular degeneration." The EC approval was based on the Phase 3 clinical trials conducted by Alteogen Biologics in 12 countries, including Europe, South Korea and Japan from June 2022 to February 2024. The comparative clinical evaluation involving...
Sanguine Biosciences, a leading provider of healthy and disease-state human biospecimens and data for research, today announced the expansion of its oncology sample offerings through new partnerships with oncology clinics nationwide. These...
syndrome, with early insights into managing gastrointestinal (GI) symptoms in the real world among patients receiving up to 12 months of treatment with DAYBUE. “These findings from LOTUS help deepen our understanding of the potential outcomes...
announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who...
therapies to treat patients with cancer, today presented new plixorafenib results from the previously completed Phase 1/2a clinical trial that demonstrate treatment with plixorafenib in patients with BRAF-altered papillary thyroid cancer (PTC) and...
Transdermal System at the upcoming Pulmonary Hypertension Professional Network (PHPN) Symposium, taking place September 18–20, 2025, in Seattle, Washington. The presentation will feature preclinical pharmacokinetic and safety data for the TRX-248...
showing the pre-clinical drug discovery pipeline for radiopharmaceuticals is attached. Adapted from Pharmaceutics 2023, 15(5), 1378 About Medicines Discovery Catapult Medicines Discovery Catapult (MDC) is a national Life Sciences service dedicated...